We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · September 22, 2020

Trofinetide Shows Potential for Treating Fragile X Syndrome

Pediatric Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

Pediatric Neurology
A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome
Pediatr. Neurol. 2020 Sep 01;110(xx)30-41, E Berry-Kravis, JP Horrigan, N Tartaglia, R Hagerman, A Kolevzon, CA Erickson, S Hatti, M Snape, A Yaroshinsky, G Stoms, FXS-001 Investigators, L Glass, NE Jones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading